Skip to main content
39°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Biodesix, Inc.
< Previous
1
2
3
Next >
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
July 20, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
July 19, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
June 07, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Research Agreement with Top US Cancer Center
June 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
June 01, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
May 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces First Quarter 2022 Results and Highlights
May 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
April 27, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
April 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer
March 29, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
February 28, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022
February 22, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)
February 14, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 09, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results
January 18, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
January 04, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors
December 08, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
November 18, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Third Quarter 2021 Results and Highlights
November 15, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
November 12, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
November 11, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
November 01, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
October 13, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
September 16, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
September 02, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
August 25, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Second Quarter 2021 Results and Highlights
August 10, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference
August 02, 2021
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.